⌘K
t
Beximco Pharmaceuticals Limited shareholders passed all resolutions at the company's Annual General Meeting held virtually on 29 December 2024. This included approval of a 40% cash dividend for the year ended 30 June 2024, equivalent to Taka 4.0 per ordinary share/GDR, payable on or before 28 January 2025 to holders on record as of 25 November 2024. Additionally, a Special Resolution was passed to change the company's name from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC."
| Date | 30 Dec 2024 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 5683R |
30 December 2024
BEXIMCO PHARMACEUTICALS LIMITED
Annual General Meeting Statement
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that all resolutions put before shareholders at the Company's Annual General Meeting ("AGM") held virtually on 29 December 2024 were duly passed.
The resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of Taka 10 (Taka 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
Additionally, the Special Resolution to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC." as per the provision of the Companies Act, 1994 (as amended in 2020) and to effect the change of the name in the relevant Clauses of the Memorandum and Articles of Association of the Company was passed. Further announcements will be made in due course when the name change will come into effect.
The Annual Report for 2023-24 is available from the Company's website, which includes the audited accounts and a review of operations for the year ended on 30 June 2024.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
S M Rabbur Reza, Chief Operating Officer Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Victoria Foster Mitchell / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.